These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30268471)

  • 1. Antibody drug conjugates in thoracic malignancies.
    Pacheco JM; Camidge DR
    Lung Cancer; 2018 Oct; 124():260-269. PubMed ID: 30268471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic Therapy in Non-Gastrointestinal Thoracic Malignancies.
    Kidane B; Hirpara D; Yasufuku K
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].
    Jassem J; Biernat W; Bryl M; Chorostowska-Wynimko J; Dziadziuszko R; Krawczyk P; Kordek R; Kowalski DM; Krzakowski M; Olszewski W; Orłowski T; Ramlau R; Rzyman W
    Pneumonol Alergol Pol; 2014; 82(2):133-49. PubMed ID: 24615197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies.
    Xie H; Adjei AA
    J Thorac Oncol; 2019 Mar; 14(3):358-376. PubMed ID: 30599202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IASLC 2020 World Conference on Lung Cancer.
    Venkatesan P
    Lancet Respir Med; 2020 Oct; 8(10):e76. PubMed ID: 32866439
    [No Abstract]   [Full Text] [Related]  

  • 6. Tremelimumab for the treatment of malignant mesothelioma.
    Guazzelli A; Hussain M; Krstic-Demonacos M; Mutti L
    Expert Opin Biol Ther; 2015; 15(12):1819-29. PubMed ID: 26560442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges.
    Payan S; Montana M; Curti C; Greillier L; Vanelle P
    Target Oncol; 2020 Aug; 15(4):429-448. PubMed ID: 32725438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repositioning PARP inhibitors in the treatment of thoracic malignancies.
    Passiglia F; Reale ML; Cetoretta V; Parlagreco E; Jacobs F; Listì A; Righi L; Bironzo P; Novello S; Scagliotti GV
    Cancer Treat Rev; 2021 Sep; 99():102256. PubMed ID: 34261032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: 'High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
    Hara A; Matsuda M; Ishii A; Yoshioka T
    Eur J Cancer; 2021 Aug; 153():265-266. PubMed ID: 34034931
    [No Abstract]   [Full Text] [Related]  

  • 10. Pemetrexed and its emerging role in the treatment of thoracic malignancies.
    Scagliotti GV; Novello S
    Expert Opin Investig Drugs; 2003 May; 12(5):853-63. PubMed ID: 12720495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
    Cantini L; Pecci F; Dammeijer F; Aerts JGJV; Berardi R
    Eur J Cancer; 2021 Aug; 153():267-269. PubMed ID: 34154882
    [No Abstract]   [Full Text] [Related]  

  • 12. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
    Abuhelwa Z; Alloghbi A; Nagasaka M
    Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
    Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
    Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
    Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
    J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed in the treatment of thoracic malignancies: a single centre experience in Singapore.
    Lopes G; Chopra A; Kukutschka J; Portillo P; Bharwani L; Chang A
    Singapore Med J; 2011 Mar; 52(3):190-4. PubMed ID: 21451928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
    Lievense LA; Bezemer K; Cornelissen R; Kaijen-Lambers ME; Hegmans JP; Aerts JG
    Lung Cancer; 2017 May; 107():36-40. PubMed ID: 27168021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapies for malignant pleural mesothelioma.
    Scherpereel A; Wallyn F; Albelda SM; Munck C
    Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eve of the third millennium, providing an update on the management of non-small cell lung cancer (NSCLC).
    Le Chevalier T
    Anticancer Drugs; 2001 Jul; 12 Suppl 3():S1. PubMed ID: 11556248
    [No Abstract]   [Full Text] [Related]  

  • 19. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug carrier nanosystems in malignant pleural mesothelioma].
    Turgut Coşan D; Ak G; Dağ İ; Soyocak A; Dikmen G; Dal A; Güneş HV; Metintaş M
    Tuberk Toraks; 2016 Mar; 64(1):60-8. PubMed ID: 27266287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.